revumenib
syndax pharma
['leukemia', 'revumenib']
inhibiting menin with revumenib yields encouraging responses for advanced acute leukemias with kmt2a rearrangements or mutant npm1, according to a study presented at #ash22 by our dr. ghayas issa: #leukemia #endcancer
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789